Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

Overview

The purpose of this study is to compare the safety and effectiveness of various doses of Replagal in patients with cardiomyopathy due to Fabry disease.

Full Title of Study: “A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 1, 2012

Detailed Description

Fabry disease is an inherited, metabolic disease caused by mutations in the GALA gene. Patients with Fabry disease accumulate a complex glycosphingolipid named globotriaosylceramide (Gb3) in various tissues and organs. All organs are affected in Fabry disease but the majority of the morbidity and mortality are caused by cardiac, renal and neurological dysfunction. Accumulation of Gb3 in the heart causes hypertrophic cardiomyopathy, valvular abnormalities, arrhythmias and infarctions. Replagal has been shown to reduce Gb3 from key tissues and organs, and stabilize renal function in patients with Fabry disease. Evidence suggests that Replagal reduces left ventricular mass (LVM) and improves midwall fractional shortening (MFS) of the heart. Left ventricular hypertrophy is a major cause of morbidity and mortality in patients with Fabry disease. This is a study of the safety and effectiveness of 3 dosing regimens of Replagal in adult patients with left ventricular hypertrophy due to Fabry disease. The primary objective of the study is to compare the effects of 2 dosing regimens of Replagal (0.2 mg/kg IV every other week and 0.2 mg/kg IV weekly) on the reduction of left ventricular mass as measured by echocardiography. The secondary objectives of this study are to compare the effects of 2 dosing regimens of Replagal (0.2 mg/kg IV every other week and 0.2 mg/kg IV weekly) on each of the following: exercise tolerance; improvement in disease-specific quality of life in heart failure patients; improvement of heart failure symptoms; magnitude of reduction in Gb3; rate of decline in renal function and improvement in the severity of proteinuria/albuminuria; and safety. An alternative treatment regimen of 0.4 mg/kg Replagal IV weekly will also be explored but without formal comparison to the 0.2 mg/kg regimens. The investigation of the safety and efficacy of the 0.4 mg/kg IV weekly regimen is a secondary objective of this study.

Interventions

  • Biological: Replagal
    • Intravenous (IV) infusion for 12 months

Arms, Groups and Cohorts

  • Active Comparator: Replagal 0.2 mg/kg, IV, every other week
    • Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.
  • Active Comparator: Replagal 0.2 mg/kg, IV, weekly
    • Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.
  • Active Comparator: Replagal 0.4 mg/kg, IV, weekly
    • Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI)
    • Time Frame: Baseline, Month 12 (Week 53)
    • Left ventricular mass (LVM) was measured through echocardiography.

Secondary Measures

  • Change From Baseline to Month 12 in Maximal Oxygen Consumption (VO2 Max) at Peak Exercise
    • Time Frame: Baseline, Month 12 (Week 53)
    • Exercise tolerance as measured by VO2 max at peak exercise using the standard exponential exercise protocol (STEEP).
  • Change From Baseline to Month 12 in Distance Walked in 6-Minute Walk Test (6MWT)
    • Time Frame: Baseline, Month 12 (Week 53)
    • Exercise tolerance using the 6MWT was measured as the total distance walked in 6 minutes.
  • Change From Baseline to Month 12 in the Minnesota Living With Heart Failure Questionnaire (MLHF-Q) Summary Score
    • Time Frame: Baseline, Month 12 (Week 53)
    • Quality of life (QoL) was evaluated using the MLHF-Q, version 2. The questionnaire is designed to assess the degree to which heart failure symptoms affect a patient’s daily life. The summary score ranges from 0 to 105, with a score of 105 representing the highest adverse impact on a patient’s QoL.
  • Change From Baseline to Month 12 in New York Heart Association (NYHA) Functional Class
    • Time Frame: Baseline, Month 12 (Week 53)
    • The NYHA functional classification system relates symptoms to everyday activities and the patient’s quality of life. NYHA Classification – The Stages of Heart Failure: Class I (Mild): No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath). Class II (Mild): Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. Class III (Moderate): Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV (Severe): Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.
  • Change From Baseline to Month 12 in Plasma Globotriaosylceramide (GB3)
    • Time Frame: Baseline, Month 12 (Week 53)
  • Change From Baseline to Month 12 in Estimated Glomerular Filtration Rate (eGFR)
    • Time Frame: Baseline, Month 12 (Week 53)
    • Renal function was assessed by an evaluation of change from baseline to Month 12 in eGFR as calculated using the Modification of Diet for Renal Disease (MDRD) equation.
  • Change From Baseline to Month 12 in Urinary Albumin/Creatinine (A/Cr) Ratio
    • Time Frame: Baseline, Month 12 (Week 53)
  • Safety Evaluation
    • Time Frame: 56 Weeks
    • Adverse events were collected throughout the study, from the time of informed consent to approximately 30 days post-final infusion.

Participating in This Clinical Trial

Inclusion Criteria

  • >18 years-old; – Male:Fabry disease confirmed by deficiency of alfa galactosidase A activity OR Female:Fabry disease confirmed by a mutation of the alfa galactosidase A gene; – ERT-naïve; – LVM/h > 50g/m2.7 for males and >47 g/m2.7 for females; – Negative pregnancy test at enrollment and contraception use required throughout study for female patients; – Signed informed consent; Exclusion Criteria:

  • Class IV heart failure; – Clinically significant hypertension; – Hemodynamically significant valvular stenosis or regurgitation; – Morbid obesity; – Known autosomal dominant sarcoplasmic contractile protein gene mutation; – Treatment with any investigational drug or device within the 30 days; – Unable to comply with the protocol as determined by the Investigator; – Positive for hepatitis B, hepatitis C or HIV

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shire
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Study Director, Study Director, Shire

Citations Reporting on Results

Małek LA, Chojnowska L, Spiewak M, Kłopotowski M, Miśko J, Petryka J, Miłosz B, Ruzyłło W. Cardiac magnetic resonance imaging in patients with Fabry's disease. Kardiol Pol. 2010 Aug;68(8):929-34.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.